Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2016-04-19 | Mr. Foley is currently the president and chief executive officer of ZELTIQ Aesthetics, Inc., a medical technology company. He holds a B.A. from the University of Notre Dame. |
| 2017-04-18 | Mr. Foley holds a B.A. from the University of Notre Dame. Mr. Foley has over 25 years of medical device operating, investment and chief executive officer experience. |
| 2018-04-18 | Mr. Foley was the chairman, president and chief executive officer of ZELTIQ Aesthetics, Inc., a medical technology company, prior to its acquisition by Allergan plc in April 2017. Mr. Foley has over 25 years of medical device operating, investment and chief executive officer experience. |
| 2019-04-17 | Mr. Foley has over 25 years of medical device operating, investment and chief executive officer experience. Mr. Foley holds a B.A. from the University of Notre Dame. |
| 2020-04-24 | Mr. Foley has over 25 years of medical device operating, investment and chief executive officer experience. We believe Mr. Foley’s previous medical device experience as a senior executive and his service on the boards of several medical device companies qualify him to serve on our Board of Directors. |
| 2021-04-22 | Mr. Foley has over 25 years of medical device operating, investment and chief executive officer experience. |
| 2022-04-19 | Mr. Foley has served as a member of our Board of Directors since 2014 and was appointed Lead Independent Director in December 2021. Mr. Foley is currently the chief executive officer of Revance Therapeutics, Inc. ... Mr. Foley holds a B.A. from the University of Notre Dame. |
| 2023-04-18 | Chief Executive Officer, Revance Therapeutics, Inc. (2019 to current); Bachelor of Arts, University of Notre Dame; no mention of software or technical skills. |
| 2024-04-16 | Chief Executive Officer, Revance Therapeutics, Inc. (2019 to current); Chairman, President and CEO, ZELTIQ Aesthetics, Inc.; Bachelor of Arts, University of Notre Dame; Over 25 years of medical device operating and investment experience. |
Data sourced from SEC filings. Last updated: 2026-02-03